Lexicon reports positive sotagliflozin trial results

Published on 12 Mar 2024 on Investing.com

Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX ) has revealed findings from a post hoc analysis of its inTandem3 Phase 3 trial, indicating ...

Read the rest of the article

Start tracking your investments with Statfolio

Key Insights Lexicon Pharmaceuticals' significant private equity firms ownership suggests that th...

Simply Wall St. · via Yahoo Finance 30 Dec 2024

Lexicon Pharmaceuticals Inc (LXRX) showcases progress in clinical developments and strategic...

GuruFocus.com · via Yahoo Finance 13 Nov 2024

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is set to release its Q3 2024 earnings on Nov 12, 2024....

GuruFocus.com · via Yahoo Finance 11 Nov 2024

Lexicon Pharmaceuticals Inc (LXRX) reports increased R&D and SG&A expenses as it advances its...

GuruFocus.com · via Yahoo Finance 11 Oct 2024

We recently compiled a list of the 10 Best Multibagger Penny Stocks of 2025. In this article, we ...

Insider Monkey · via Yahoo Finance 24 Aug 2024

Key Insights Significant control over Lexicon Pharmaceuticals by private equity firms implies tha...

Simply Wall St. · via Yahoo Finance 10 Jul 2024

Lexicon Pharmaceuticals , Inc. (NASDAQ:LXRX) announced today that CEO Lonnel Coats will retire on...

Investing.com 29 Apr 2024

Lexicon Pharmaceuticals, Inc. LXRX announced data from a new post hoc analysis of its phase III i...

Zacks via Yahoo Finance 13 Mar 2024

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points o...

Benzinga 12 Mar 2024

Lexicon Pharmaceuticals , Inc. (NASDAQ: LXRX ) has revealed findings from a post hoc analysis of ...

Investing.com 12 Mar 2024